The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5‐fluorouracil
Open Access
- 9 November 2006
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 120 (3) , 694-701
Abstract
Cytotoxic effect of 5‐fluorouracil 5‐FU is mediated through inhibition of thymidylate synthase (TS), and 5‐FU is catabolised by dihydropyrimidine dehydrogenase (DPD). Efficacy of 5‐FU may therefore depend on the TS and DPD activity of colorectal cancer. Archival tumour specimens from 303 consecutive patients were analysed for the expression of TS and DPD using immunohistochemistry. All patients were completely resected for colorectal cancer stages II–III and have subsequently received adjuvant treatment with 5‐FU. In a multivariate analysis adjusting for the impact of bowel obstruction and vascular tumour invasion, diffuse TS pattern was significantly associated with increased risk of recurrence (hazard ratio (HR) = 1.9; 95% confidence interval (CI): 1.1–3.2; p = 0.02), but without significant association to death (HR = 1.6; 95% CI: 0.9–2.8; p = 0.08). High TS intensity was not significantly associated with lower risk of recurrence (HR = 0.6; 95% CI: 0.3–1.1; p = 0.07) or death (HR = 0.6; 95% CI: 0.3–1.2; p = 0.2). High DPD intensity was significantly associated with increased risk of recurrence (HR = 1.5; 95% CI: 1.1–2.3; p = 0.03) and death (HR = 1.6; 95% CI: 1.1–2.5; p = 0.02). Patients with a combination of low TS and high DPD intensity were at significantly increased risk of both recurrence (HR = 2.1; 95% CI: 1.0–4.2; p = 0.04) and death (HR = 2.0; 95% CI: 1.0–4.0; p = 0.05). No relationship between tolerability and toxicity of 5‐FU and TS and DPD expression was found. It is concluded that characterizing colorectal carcinomas by TS and DPD expression may disclose subsets of patients with significantly greater risk of disease recurrence and early death. This may be utilized in the selection of patients for treatment approaches and for decision on follow‐up programs.Keywords
This publication has 40 references indexed in Scilit:
- Prognostic and predictive value of the thymidylate synthase expression in patients with non-metastatic colorectal cancerEuropean Journal of Surgical Oncology, 2005
- Detection of Thymidylate Synthase Expression in Lymph Node Metastases of Colorectal Cancer Can Improve the Prognostic InformationJournal of Clinical Oncology, 2005
- Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patientsAnnals of Oncology, 2005
- Thymidylate Synthase and Methylenetetrahydrofolate Reductase Gene Polymorphism in Normal Tissue As Predictors of Fluorouracil SensitivityJournal of Clinical Oncology, 2005
- Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5‐FU‐based neo‐adjuvant chemoradiotherapy in rectal cancerThe Journal of Pathology, 2004
- Thymidylate Synthase Expression in Normal Colonic Mucosa: A Predictive Marker of Toxicity in Colorectal Cancer Patients Receiving 5-Fluorouracil-Based Adjuvant ChemotherapyOncology, 2004
- Topoisomerase‐I, thymidylate synthase primary tumour expression and clinical efficacy of 5‐FU/CPT‐11 chemotherapy in advanced colorectal cancer patientsInternational Journal of Cancer, 2004
- Thymidylate Synthase Protein Expression in Primary Colorectal Cancer: Lack of Correlation With Outcome and Response to Fluorouracil in Metastatic Disease SitesJournal of Clinical Oncology, 2003
- Prognostic Value of Thymidylate Synthase, Ki-67, and p53 in Patients With Dukes’ B and C Colon Cancer: A National Cancer Institute–National Surgical Adjuvant Breast and Bowel Project Collaborative StudyJournal of Clinical Oncology, 2003
- Increased risk of grade IV neutropenia after administration of 5‐fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: High prevalence of the IVS14+1g>a mutationInternational Journal of Cancer, 2002